47 results about "RIG-I" patented technology

This invention discloses immunostimulatory combinations of Tumor Necrosis Factor Receptor Superfamily (TN-FRSF) agonists, Toll-Like Receptor (TLR) agonists, “domain present in NAIP, CIITA, HET-E, TP-I (NACHT)-Leucine Rich Repeat (LRR)” or “NLR” agonists, RIG-I-Like Helicase or “RLH” agonists, purinergic receptor agonists and cytokine/chemokine receptor agonists, together with delivery methods. The combinations, when used alone at the site of pathology, provide immunostimulation that induces host humoral and cellular immunologic responses to eliminate pathogens or neoplasms. Alternatively, when the combinations are used with a defined antigens, these combinations can induce focused humoral and cellular immunologic responses useful as prophylactic and/or ameliorative therapeutic modalities for infections and the treatment of neoplastic disorders.

Disclosed herein are compounds and related compositions for the treatment of viral infection, including RNA viral infection, and compounds that can modulate the RIG-I pathway in vertebrate cells, including compounds that can activate the RIG-I pathway.

Disclosed herein are compounds and related compositions for the treatment of viral infection, including RNA viral infection, and compounds that can modulate the RIG-I pathway in vertebrate cells, including compounds that can activate the RIG-I pathway.

Disclosed herein are compounds and related compositions for the treatment of viral infection, including RNA viral infection, and compounds that can modulate the RIG-I pathway in vertebrate cells, including compounds that can activate the RIG-I pathway.

Disclosed herein are compounds and related compositions for the treatment of viral infection, including RNA viral infection, and compounds that can modulate the RIG-I pathway in vertebrate cells, including compounds that can activate the RIG-I pathway.

The invention relates to the fields of biotechnology and medical diagnosis. The research finds that the molecular expression of a pattern recognition receptor RIG-I in the tumor tissue of a tumor patient is obviously decreased and the correlation exists between the decreasing amplitude and the survival time of the tumor patient; moreover, the low expression of the molecules of the pattern recognition receptor RIG-I is significantly correlated with the prognosis difference of the patient. The invention provides an application of the pattern recognition receptor RIG-I in preparation of a kit for tumor diagnosis or prognosis evaluation, and the corresponding detection kit.

The invention belongs to the technical field of preparing a molecular marker of fish, and particularly relates to the molecular marker for a hemorrhagic disease resistance trait of grass carp and the application of the molecular marker. The molecular marker is obtained through grass carp RIG-I (Retinoic Acid-Induced Gene I) gene cloning and transcriptome sequencing; a nucleotide sequence of the molecular marker is as shown in a sequence table SEQ ID NO.1, and the insertion (deletion) (which is as shown in a sequence table SEQ ID NO.2) of amino acids located in 211 to 215 of RIG-I protein of the grass carp is caused by the insertion (the deletion) of a segment of 15bp base fragments of a basic group located in 665 of the SEQ ID NO.1. A GCRV (Grass Carp Reovirus) infection test shows that the death rate of gene inserting type grass carp is obviously lower than that of deletion type grass carp, thereby showing that the mutation of the segment of basic group of the RIG-I gene of the grass carp is related to the grass carp hemorrhagic disease resistance trait. According to the molecular marker disclosed by the invention, a new molecular marker is provided for marker assisted selection of the hemorrhagic disease resistance trait of the grass carp.

Disclosed herein are compounds and related compositions for the treatment of viral infection, including RNA viral infection, and compounds that can modulate the RIG-I pathway in vertebrate cells, including compounds that can activate the RIG-I pathway.

Disclosed herein are methods for identifying compounds for the treatment of viral infection, including RNA viral infection and uses of the compounds as pharmaceutical compositions. The identified compounds modulate the RIG-I pathway in vertebrate cells.

The present invention comprises Rig I agonists for enhancing the effects of cytotoxic cells and stem Cells. The Rig I agonists can be used in vivo as small molecule therapeutics or in vitro to enhance cells for adoptive cell transfer. Applications include cancer therapy, immune system enhancement, chronic viral infection and treatment of viral induced inflammation and enhancement of virus based therapies.

The invention relates to a synthesis method of difunctional 5'-ppp-siRNA (3p-siRNA) for efficiently and specifically inhibiting the replication of hepatitis B viruses (HBVs), and an application of the 3p-siRNA. The 3p-siRNA specifically inhibit the HBV target gene expression through an RNAi mechanism, activates the host interferon expression through an RIG-I dependence mechanism, has an antivirus effect through antiviral natural immunoreactions, and is difunctional anti-HBV novel 3p-siRNA simultaneously having the effects of RNAi and the activation of the host antiviral natural immunoreactions; and the 3p-siRNA has a small toxicity, can efficiently activate the RIG-I mediated host natural antiviral interferon (IFN) expression, can substantially inhibit the HBeAg and HBsAg secretion and the DNA replication of the HBVs, and has an obvious dosage dependency. The anti-HBV difunctional 3p-siRNA is prepared through adopting an in-vitro transcription method and an artificial chemical synthesis method, and can be used for the researches and exploitation of novel HBV medicines. The difunctional 3p-siRNA can be used for the researches and exploitation of other important human viral and bacterial nucleic acid novel medicines.

Disclosed herein are compounds and related compositions for the treatment of viral infection, including RNA viral infection, and compounds that can modulate the RIG-I pathway in vertebrate cells, including compounds that can activate the RIG-I pathway.

The invention relates to the field of biotechnology and medical diagnosis. According to the invention, molecule-pattern recognition receptors RIG-I with tumor expression correlation and having regulation effect on the growth of cancer cells are screened out from gene chip. The invention further provides application of the pattern recognition receptors RIG-I in preparation of anticancer drugs; the application specifically refers to combination between the pattern recognition receptors RIG-I and interferon alpha. The invention provides a new idea for oncotherapy.

The invention relates to the field of biotechnology and particularly relates to an application of a p97 gene for therapy of virus infection and a related medicine thereof. For the first time, the invention discloses that a p97-Npl4 compound formed by combining the p97 with an assistant factor Npl4 can promote degradation of RIG-I by promoting K48 chain ubiquitination of the RIG-I, which is mediated by RNF125, thereby inhibiting RIG-I-mediated IFN[beta] signal channel, and finally achieving the effect of reducing anti-virus infection capability. On the basis of the mentioned mechanism, an inhibitor, which can effectively block the interaction of the p97 and the Npl4, is screened out, wherein the inhibitor can promote the RIG-I-mediated IFN[beta] signal channel, thus improving the anti-virus infection capability and further achieving the effects of therapy on the virus infection. The application has great clinical and market value.

The invention discloses a difunctional 5'-tri-phosphate siGPC-3, a preparation method and application thereof. The difunctional 5'-tri-phosphate siGPC-3 is GPC-3 specific siRNA containing a triphosphate group, the sequence of a sense strand from 5' to 3' is CCUUGCAGAACUGGCCUAU, wherein the 5' end is modified with a triphosphate group, the sequence of an antisense strand from 5' to 3' is AUAGGCCAGUUCUGCAAGG, and the 5' end of the antisense strand is modified with a triphosphate group. The difunctional 5'-tri-phosphate siGPC-3 has both gene silencing function and RIG-I activation function.